Holdco Nuvo Group D.G Ltd. Ordinary Shares (NUVO) Stock Competitors & Peer Comparison
See (NUVO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUVO | $0.17 | +0.00% | 5.7M | -0.17 | -$1.01 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $99.67 | -1.96% | 173.6B | 19.13 | $5.21 | +2.49% |
| ISRG | $350.06 | -0.88% | 124B | 36.39 | $9.62 | N/A |
| SYK | $314.58 | -1.43% | 120.6B | 23.50 | $13.39 | +1.10% |
| MDT | $82.35 | -1.13% | 105.4B | 14.89 | $5.53 | +3.47% |
| BSX | $43.19 | -1.33% | 64.2B | 13.93 | $3.10 | N/A |
| EW | $84.55 | -0.53% | 48.7B | 31.33 | $2.70 | N/A |
| DXCM | $74.75 | -1.24% | 28.8B | 32.08 | $2.33 | N/A |
| RMD | $195.80 | -1.41% | 28.4B | 18.18 | $10.77 | +1.23% |
Stock Comparison
NUVO vs BSX-PA Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NUVO is priced at $0.17, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NUVO's ROE is -0.37%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NUVO is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BSX-PA's competition here
NUVO vs ABT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ABT has a market cap of 173.6B. Regarding current trading prices, NUVO is priced at $0.17, while ABT trades at $99.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ABT's P/E ratio is 19.13. In terms of profitability, NUVO's ROE is -0.37%, compared to ABT's ROE of +0.12%. Regarding short-term risk, NUVO is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ABT's competition here
NUVO vs ISRG Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ISRG has a market cap of 124B. Regarding current trading prices, NUVO is priced at $0.17, while ISRG trades at $350.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ISRG's P/E ratio is 36.39. In terms of profitability, NUVO's ROE is -0.37%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, NUVO is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ISRG's competition here
NUVO vs SYK Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SYK has a market cap of 120.6B. Regarding current trading prices, NUVO is priced at $0.17, while SYK trades at $314.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SYK's P/E ratio is 23.50. In terms of profitability, NUVO's ROE is -0.37%, compared to SYK's ROE of +0.15%. Regarding short-term risk, NUVO is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SYK's competition here
NUVO vs MDT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, MDT has a market cap of 105.4B. Regarding current trading prices, NUVO is priced at $0.17, while MDT trades at $82.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas MDT's P/E ratio is 14.89. In terms of profitability, NUVO's ROE is -0.37%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NUVO is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check MDT's competition here
NUVO vs BSX Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BSX has a market cap of 64.2B. Regarding current trading prices, NUVO is priced at $0.17, while BSX trades at $43.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BSX's P/E ratio is 13.93. In terms of profitability, NUVO's ROE is -0.37%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NUVO is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BSX's competition here
NUVO vs EW Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, EW has a market cap of 48.7B. Regarding current trading prices, NUVO is priced at $0.17, while EW trades at $84.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas EW's P/E ratio is 31.33. In terms of profitability, NUVO's ROE is -0.37%, compared to EW's ROE of +0.11%. Regarding short-term risk, NUVO is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check EW's competition here
NUVO vs DXCM Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, DXCM has a market cap of 28.8B. Regarding current trading prices, NUVO is priced at $0.17, while DXCM trades at $74.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas DXCM's P/E ratio is 32.08. In terms of profitability, NUVO's ROE is -0.37%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, NUVO is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check DXCM's competition here
NUVO vs RMD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, RMD has a market cap of 28.4B. Regarding current trading prices, NUVO is priced at $0.17, while RMD trades at $195.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas RMD's P/E ratio is 18.18. In terms of profitability, NUVO's ROE is -0.37%, compared to RMD's ROE of +0.24%. Regarding short-term risk, NUVO is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check RMD's competition here
NUVO vs ZBH Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ZBH has a market cap of 17.2B. Regarding current trading prices, NUVO is priced at $0.17, while ZBH trades at $88.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ZBH's P/E ratio is 10.48. In terms of profitability, NUVO's ROE is -0.37%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NUVO is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ZBH's competition here
NUVO vs ABMD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NUVO is priced at $0.17, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NUVO's ROE is -0.37%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NUVO is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ABMD's competition here
NUVO vs SNN Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, NUVO is priced at $0.17, while SNN trades at $30.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SNN's P/E ratio is 16.30. In terms of profitability, NUVO's ROE is -0.37%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NUVO is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SNN's competition here
NUVO vs ALGN Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ALGN has a market cap of 12.7B. Regarding current trading prices, NUVO is priced at $0.17, while ALGN trades at $177.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ALGN's P/E ratio is 16.18. In terms of profitability, NUVO's ROE is -0.37%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, NUVO is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ALGN's competition here
NUVO vs SWAV Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NUVO is priced at $0.17, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NUVO's ROE is -0.37%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NUVO is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SWAV's competition here
NUVO vs PEN Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, NUVO is priced at $0.17, while PEN trades at $317.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PEN's P/E ratio is 82.90. In terms of profitability, NUVO's ROE is -0.37%, compared to PEN's ROE of +0.12%. Regarding short-term risk, NUVO is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PEN's competition here
NUVO vs PODD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PODD has a market cap of 11.3B. Regarding current trading prices, NUVO is priced at $0.17, while PODD trades at $163.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PODD's P/E ratio is 30.43. In terms of profitability, NUVO's ROE is -0.37%, compared to PODD's ROE of +0.21%. Regarding short-term risk, NUVO is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PODD's competition here
NUVO vs GMED Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, GMED has a market cap of 10.3B. Regarding current trading prices, NUVO is priced at $0.17, while GMED trades at $76.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas GMED's P/E ratio is 17.13. In terms of profitability, NUVO's ROE is -0.37%, compared to GMED's ROE of +0.13%. Regarding short-term risk, NUVO is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check GMED's competition here
NUVO vs MASI Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, NUVO is priced at $0.17, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas MASI's P/E ratio is 44.43. In terms of profitability, NUVO's ROE is -0.37%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NUVO and MASI have similar daily volatility (0.00).Check MASI's competition here
NUVO vs BRKR Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BRKR has a market cap of 9.2B. Regarding current trading prices, NUVO is priced at $0.17, while BRKR trades at $60.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BRKR's P/E ratio is 33.20. In terms of profitability, NUVO's ROE is -0.37%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, NUVO is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BRKR's competition here
NUVO vs GKOS Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, GKOS has a market cap of 9B. Regarding current trading prices, NUVO is priced at $0.17, while GKOS trades at $153.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas GKOS's P/E ratio is -178.08. In terms of profitability, NUVO's ROE is -0.37%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, NUVO is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check GKOS's competition here
NUVO vs BIO-B Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BIO-B has a market cap of 8.4B. Regarding current trading prices, NUVO is priced at $0.17, while BIO-B trades at $317.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BIO-B's P/E ratio is 94.29. In terms of profitability, NUVO's ROE is -0.37%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, NUVO is less volatile compared to BIO-B. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BIO-B's competition here
NUVO vs BIO Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, NUVO is priced at $0.17, while BIO trades at $301.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BIO's P/E ratio is 32.55. In terms of profitability, NUVO's ROE is -0.37%, compared to BIO's ROE of +0.02%. Regarding short-term risk, NUVO is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BIO's competition here
NUVO vs NARI Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NUVO is priced at $0.17, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NARI's P/E ratio is -59.24. In terms of profitability, NUVO's ROE is -0.37%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NUVO is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NARI's competition here
NUVO vs LIVN Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, NUVO is priced at $0.17, while LIVN trades at $79.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas LIVN's P/E ratio is 19.96. In terms of profitability, NUVO's ROE is -0.37%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, NUVO is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check LIVN's competition here
NUVO vs AXNX Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NUVO is priced at $0.17, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NUVO's ROE is -0.37%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NUVO and AXNX have similar daily volatility (0.00).Check AXNX's competition here
NUVO vs IRTC Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, NUVO is priced at $0.17, while IRTC trades at $109.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas IRTC's P/E ratio is -194.64. In terms of profitability, NUVO's ROE is -0.37%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, NUVO is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check IRTC's competition here
NUVO vs ITGR Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ITGR has a market cap of 3.3B. Regarding current trading prices, NUVO is priced at $0.17, while ITGR trades at $96.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ITGR's P/E ratio is 15.30. In terms of profitability, NUVO's ROE is -0.37%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, NUVO is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ITGR's competition here
NUVO vs ESTA Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ESTA has a market cap of 2.8B. Regarding current trading prices, NUVO is priced at $0.17, while ESTA trades at $95.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ESTA's P/E ratio is -66.42. In terms of profitability, NUVO's ROE is -0.37%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, NUVO is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ESTA's competition here
NUVO vs TMDX Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, NUVO is priced at $0.17, while TMDX trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TMDX's P/E ratio is 30.32. In terms of profitability, NUVO's ROE is -0.37%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, NUVO is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TMDX's competition here
NUVO vs AXGN Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, NUVO is priced at $0.17, while AXGN trades at $40.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AXGN's P/E ratio is 105.95. In terms of profitability, NUVO's ROE is -0.37%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, NUVO is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AXGN's competition here
NUVO vs NUVA Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NUVO is priced at $0.17, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NUVO's ROE is -0.37%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NUVO is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NUVA's competition here
NUVO vs UFPT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, NUVO is priced at $0.17, while UFPT trades at $243.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas UFPT's P/E ratio is 25.41. In terms of profitability, NUVO's ROE is -0.37%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NUVO is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check UFPT's competition here
NUVO vs NVCR Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, NUVO is priced at $0.17, while NVCR trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NVCR's P/E ratio is -10.45. In terms of profitability, NUVO's ROE is -0.37%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, NUVO is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NVCR's competition here
NUVO vs BFLY Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BFLY has a market cap of 1.8B. Regarding current trading prices, NUVO is priced at $0.17, while BFLY trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BFLY's P/E ratio is -28.46. In terms of profitability, NUVO's ROE is -0.37%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, NUVO is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BFLY's competition here
NUVO vs ENOV Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, NUVO is priced at $0.17, while ENOV trades at $27.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ENOV's P/E ratio is 8.01. In terms of profitability, NUVO's ROE is -0.37%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, NUVO is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ENOV's competition here
NUVO vs AHCO Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, NUVO is priced at $0.17, while AHCO trades at $11.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AHCO's P/E ratio is 25.48. In terms of profitability, NUVO's ROE is -0.37%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, NUVO is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AHCO's competition here
NUVO vs INSP Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, INSP has a market cap of 1.5B. Regarding current trading prices, NUVO is priced at $0.17, while INSP trades at $52.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas INSP's P/E ratio is 20.33. In terms of profitability, NUVO's ROE is -0.37%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NUVO is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check INSP's competition here
NUVO vs IART Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, IART has a market cap of 1.5B. Regarding current trading prices, NUVO is priced at $0.17, while IART trades at $19.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas IART's P/E ratio is 8.06. In terms of profitability, NUVO's ROE is -0.37%, compared to IART's ROE of -0.48%. Regarding short-term risk, NUVO is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check IART's competition here
NUVO vs HSKA Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NUVO is priced at $0.17, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NUVO's ROE is -0.37%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NUVO and HSKA have similar daily volatility (0.00).Check HSKA's competition here
NUVO vs ATEC Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, NUVO is priced at $0.17, while ATEC trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ATEC's P/E ratio is -75.45. In terms of profitability, NUVO's ROE is -0.37%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, NUVO is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ATEC's competition here
NUVO vs CNMD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CNMD has a market cap of 1.3B. Regarding current trading prices, NUVO is priced at $0.17, while CNMD trades at $41.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CNMD's P/E ratio is 9.20. In terms of profitability, NUVO's ROE is -0.37%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, NUVO is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CNMD's competition here
NUVO vs IRMD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, NUVO is priced at $0.17, while IRMD trades at $94.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas IRMD's P/E ratio is 47.72. In terms of profitability, NUVO's ROE is -0.37%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, NUVO is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check IRMD's competition here
NUVO vs AORT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, NUVO is priced at $0.17, while AORT trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AORT's P/E ratio is 38.42. In terms of profitability, NUVO's ROE is -0.37%, compared to AORT's ROE of +0.03%. Regarding short-term risk, NUVO is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AORT's competition here
NUVO vs TNDM Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, NUVO is priced at $0.17, while TNDM trades at $17.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TNDM's P/E ratio is -16.00. In terms of profitability, NUVO's ROE is -0.37%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, NUVO is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TNDM's competition here
NUVO vs AVNS Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NUVO is priced at $0.17, while AVNS trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AVNS's P/E ratio is 27.76. In terms of profitability, NUVO's ROE is -0.37%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NUVO is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AVNS's competition here
NUVO vs SILK Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SILK's P/E ratio is -18.96. In terms of profitability, NUVO's ROE is -0.37%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NUVO is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SILK's competition here
NUVO vs FNA Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas FNA's P/E ratio is -19.83. In terms of profitability, NUVO's ROE is -0.37%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NUVO is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check FNA's competition here
NUVO vs LMRI Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while LMRI trades at $11.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas LMRI's P/E ratio is -21.65. In terms of profitability, NUVO's ROE is -0.37%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, NUVO is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check LMRI's competition here
NUVO vs PRCT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while PRCT trades at $18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PRCT's P/E ratio is -10.18. In terms of profitability, NUVO's ROE is -0.37%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, NUVO is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PRCT's competition here
NUVO vs INMD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, INMD has a market cap of 882.9M. Regarding current trading prices, NUVO is priced at $0.17, while INMD trades at $15.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas INMD's P/E ratio is 9.85. In terms of profitability, NUVO's ROE is -0.37%, compared to INMD's ROE of +0.13%. Regarding short-term risk, NUVO is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check INMD's competition here
NUVO vs CSII Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NUVO is priced at $0.17, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CSII's P/E ratio is -20.83. In terms of profitability, NUVO's ROE is -0.37%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NUVO is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CSII's competition here
NUVO vs BVS Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BVS has a market cap of 804.8M. Regarding current trading prices, NUVO is priced at $0.17, while BVS trades at $11.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BVS's P/E ratio is 15.84. In terms of profitability, NUVO's ROE is -0.37%, compared to BVS's ROE of +0.16%. Regarding short-term risk, NUVO is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BVS's competition here
NUVO vs SIBN Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SIBN has a market cap of 755.7M. Regarding current trading prices, NUVO is priced at $0.17, while SIBN trades at $17.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SIBN's P/E ratio is -43.69. In terms of profitability, NUVO's ROE is -0.37%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, NUVO is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SIBN's competition here
NUVO vs SSII Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SSII has a market cap of 716.5M. Regarding current trading prices, NUVO is priced at $0.17, while SSII trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SSII's P/E ratio is -69.83. In terms of profitability, NUVO's ROE is -0.37%, compared to SSII's ROE of -0.23%. Regarding short-term risk, NUVO is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SSII's competition here
NUVO vs CBLL Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CBLL has a market cap of 678.8M. Regarding current trading prices, NUVO is priced at $0.17, while CBLL trades at $17.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CBLL's P/E ratio is -10.98. In terms of profitability, NUVO's ROE is -0.37%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, NUVO is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CBLL's competition here
NUVO vs TCMD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TCMD has a market cap of 641.3M. Regarding current trading prices, NUVO is priced at $0.17, while TCMD trades at $28.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TCMD's P/E ratio is 32.31. In terms of profitability, NUVO's ROE is -0.37%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, NUVO is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TCMD's competition here
NUVO vs BWAY Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BWAY has a market cap of 633.5M. Regarding current trading prices, NUVO is priced at $0.17, while BWAY trades at $16.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BWAY's P/E ratio is 41.03. In terms of profitability, NUVO's ROE is -0.37%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, NUVO is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BWAY's competition here
NUVO vs CERS Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CERS has a market cap of 625.2M. Regarding current trading prices, NUVO is priced at $0.17, while CERS trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CERS's P/E ratio is -62.28. In terms of profitability, NUVO's ROE is -0.37%, compared to CERS's ROE of -0.15%. Regarding short-term risk, NUVO is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CERS's competition here
NUVO vs SRDX Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NUVO is priced at $0.17, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NUVO's ROE is -0.37%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, NUVO and SRDX have similar daily volatility (0.00).Check SRDX's competition here
NUVO vs CTKB Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CTKB has a market cap of 590.2M. Regarding current trading prices, NUVO is priced at $0.17, while CTKB trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CTKB's P/E ratio is -35.15. In terms of profitability, NUVO's ROE is -0.37%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, NUVO is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CTKB's competition here
NUVO vs APEN Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NUVO is priced at $0.17, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas APEN's P/E ratio is -9.43. In terms of profitability, NUVO's ROE is -0.37%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NUVO is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check APEN's competition here
NUVO vs ZIMV Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NUVO is priced at $0.17, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NUVO's ROE is -0.37%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, NUVO and ZIMV have similar daily volatility (0.00).Check ZIMV's competition here
NUVO vs NPCE Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NPCE has a market cap of 527.1M. Regarding current trading prices, NUVO is priced at $0.17, while NPCE trades at $15.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NPCE's P/E ratio is -26.66. In terms of profitability, NUVO's ROE is -0.37%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, NUVO is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NPCE's competition here
NUVO vs KIDS Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, KIDS has a market cap of 500.6M. Regarding current trading prices, NUVO is priced at $0.17, while KIDS trades at $19.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas KIDS's P/E ratio is -18.92. In terms of profitability, NUVO's ROE is -0.37%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NUVO is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check KIDS's competition here
NUVO vs OFIX Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, OFIX has a market cap of 470.1M. Regarding current trading prices, NUVO is priced at $0.17, while OFIX trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas OFIX's P/E ratio is -47.37. In terms of profitability, NUVO's ROE is -0.37%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, NUVO is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check OFIX's competition here
NUVO vs CLPT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CLPT has a market cap of 462.1M. Regarding current trading prices, NUVO is priced at $0.17, while CLPT trades at $15.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CLPT's P/E ratio is -15.26. In terms of profitability, NUVO's ROE is -0.37%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, NUVO is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CLPT's competition here
NUVO vs VREX Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, VREX has a market cap of 451.3M. Regarding current trading prices, NUVO is priced at $0.17, while VREX trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas VREX's P/E ratio is 11.28. In terms of profitability, NUVO's ROE is -0.37%, compared to VREX's ROE of -0.18%. Regarding short-term risk, NUVO is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check VREX's competition here
NUVO vs DCTH Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, DCTH has a market cap of 442.2M. Regarding current trading prices, NUVO is priced at $0.17, while DCTH trades at $12.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas DCTH's P/E ratio is 1281.00. In terms of profitability, NUVO's ROE is -0.37%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, NUVO is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check DCTH's competition here
NUVO vs PACB Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PACB has a market cap of 434.8M. Regarding current trading prices, NUVO is priced at $0.17, while PACB trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PACB's P/E ratio is -2.86. In terms of profitability, NUVO's ROE is -0.37%, compared to PACB's ROE of -4.88%. Regarding short-term risk, NUVO is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PACB's competition here
NUVO vs ELMD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ELMD has a market cap of 335.8M. Regarding current trading prices, NUVO is priced at $0.17, while ELMD trades at $40.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ELMD's P/E ratio is 34.66. In terms of profitability, NUVO's ROE is -0.37%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, NUVO is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ELMD's competition here
NUVO vs CARL Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CARL has a market cap of 312.6M. Regarding current trading prices, NUVO is priced at $0.17, while CARL trades at $11.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CARL's P/E ratio is -4.58. In terms of profitability, NUVO's ROE is -0.37%, compared to CARL's ROE of -0.62%. Regarding short-term risk, NUVO is less volatile compared to CARL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CARL's competition here
NUVO vs AVR Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AVR has a market cap of 312.3M. Regarding current trading prices, NUVO is priced at $0.17, while AVR trades at $8.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AVR's P/E ratio is -3.81. In terms of profitability, NUVO's ROE is -0.37%, compared to AVR's ROE of -1.24%. Regarding short-term risk, NUVO is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AVR's competition here
NUVO vs SMLR Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NUVO is priced at $0.17, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NUVO's ROE is -0.37%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, NUVO and SMLR have similar daily volatility (0.00).Check SMLR's competition here
NUVO vs TMCI Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TMCI has a market cap of 274.4M. Regarding current trading prices, NUVO is priced at $0.17, while TMCI trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TMCI's P/E ratio is -4.50. In terms of profitability, NUVO's ROE is -0.37%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, NUVO is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TMCI's competition here
NUVO vs SGHT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SGHT has a market cap of 267.2M. Regarding current trading prices, NUVO is priced at $0.17, while SGHT trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SGHT's P/E ratio is -6.92. In terms of profitability, NUVO's ROE is -0.37%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, NUVO is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SGHT's competition here
NUVO vs MGRM Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NUVO is priced at $0.17, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas MGRM's P/E ratio is -12.00. In terms of profitability, NUVO's ROE is -0.37%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, NUVO and MGRM have similar daily volatility (0.00).Check MGRM's competition here
NUVO vs CATX Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CATX has a market cap of 229.8M. Regarding current trading prices, NUVO is priced at $0.17, while CATX trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CATX's P/E ratio is -2.11. In terms of profitability, NUVO's ROE is -0.37%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NUVO is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CATX's competition here
NUVO vs NVRO Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NUVO is priced at $0.17, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NUVO's ROE is -0.37%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NUVO is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NVRO's competition here
NUVO vs RXST Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, RXST has a market cap of 217.3M. Regarding current trading prices, NUVO is priced at $0.17, while RXST trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas RXST's P/E ratio is -7.29. In terms of profitability, NUVO's ROE is -0.37%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NUVO is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check RXST's competition here
NUVO vs FOCL Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, FOCL has a market cap of 212.9M. Regarding current trading prices, NUVO is priced at $0.17, while FOCL trades at $5.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas FOCL's P/E ratio is -7.30. In terms of profitability, NUVO's ROE is -0.37%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, NUVO is less volatile compared to FOCL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check FOCL's competition here
NUVO vs SENS Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SENS has a market cap of 210.2M. Regarding current trading prices, NUVO is priced at $0.17, while SENS trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SENS's P/E ratio is -2.51. In terms of profitability, NUVO's ROE is -0.37%, compared to SENS's ROE of -1.30%. Regarding short-term risk, NUVO is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SENS's competition here
NUVO vs PROF Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PROF has a market cap of 209.1M. Regarding current trading prices, NUVO is priced at $0.17, while PROF trades at $6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PROF's P/E ratio is -5.57. In terms of profitability, NUVO's ROE is -0.37%, compared to PROF's ROE of -0.70%. Regarding short-term risk, NUVO is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PROF's competition here
NUVO vs ANIK Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ANIK has a market cap of 201.7M. Regarding current trading prices, NUVO is priced at $0.17, while ANIK trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ANIK's P/E ratio is 30.94. In terms of profitability, NUVO's ROE is -0.37%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, NUVO is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ANIK's competition here
NUVO vs BSGM Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NUVO is priced at $0.17, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NUVO's ROE is -0.37%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, NUVO is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BSGM's competition here
NUVO vs QTRX Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, QTRX has a market cap of 187M. Regarding current trading prices, NUVO is priced at $0.17, while QTRX trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas QTRX's P/E ratio is -2.48. In terms of profitability, NUVO's ROE is -0.37%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, NUVO is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check QTRX's competition here
NUVO vs PMI Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PMI has a market cap of 185M. Regarding current trading prices, NUVO is priced at $0.17, while PMI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PMI's P/E ratio is -0.10. In terms of profitability, NUVO's ROE is -0.37%, compared to PMI's ROE of +4.99%. Regarding short-term risk, NUVO is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PMI's competition here
NUVO vs MDGS Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NUVO is priced at $0.17, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NUVO's ROE is -0.37%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NUVO is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check MDGS's competition here
NUVO vs INGN Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, INGN has a market cap of 174.1M. Regarding current trading prices, NUVO is priced at $0.17, while INGN trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas INGN's P/E ratio is -7.07. In terms of profitability, NUVO's ROE is -0.37%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NUVO is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check INGN's competition here
NUVO vs TLSI Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TLSI has a market cap of 164.5M. Regarding current trading prices, NUVO is priced at $0.17, while TLSI trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TLSI's P/E ratio is -2.58. In terms of profitability, NUVO's ROE is -0.37%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, NUVO is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TLSI's competition here
NUVO vs QIPT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NUVO is priced at $0.17, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NUVO's ROE is -0.37%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NUVO and QIPT have similar daily volatility (0.00).Check QIPT's competition here
NUVO vs CVRX Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CVRX has a market cap of 131.9M. Regarding current trading prices, NUVO is priced at $0.17, while CVRX trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CVRX's P/E ratio is -2.46. In terms of profitability, NUVO's ROE is -0.37%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, NUVO is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CVRX's competition here
NUVO vs RCEL Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, RCEL has a market cap of 126.5M. Regarding current trading prices, NUVO is priced at $0.17, while RCEL trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas RCEL's P/E ratio is -3.24. In terms of profitability, NUVO's ROE is -0.37%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, NUVO is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check RCEL's competition here
NUVO vs ICAD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NUVO is priced at $0.17, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NUVO's ROE is -0.37%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, NUVO and ICAD have similar daily volatility (0.00).Check ICAD's competition here
NUVO vs HSDT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, HSDT has a market cap of 102.2M. Regarding current trading prices, NUVO is priced at $0.17, while HSDT trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas HSDT's P/E ratio is -0.02. In terms of profitability, NUVO's ROE is -0.37%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, NUVO is less volatile compared to HSDT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check HSDT's competition here
NUVO vs OWLT Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, OWLT has a market cap of 100.2M. Regarding current trading prices, NUVO is priced at $0.17, while OWLT trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas OWLT's P/E ratio is -39.57. In terms of profitability, NUVO's ROE is -0.37%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, NUVO is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check OWLT's competition here
NUVO vs LUCD Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, LUCD has a market cap of 98.9M. Regarding current trading prices, NUVO is priced at $0.17, while LUCD trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas LUCD's P/E ratio is -2.61. In terms of profitability, NUVO's ROE is -0.37%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, NUVO is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check LUCD's competition here
NUVO vs HJLI Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NUVO is priced at $0.17, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas HJLI's P/E ratio is N/A. In terms of profitability, NUVO's ROE is -0.37%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, NUVO is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check HJLI's competition here
NUVO vs RPID Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, RPID has a market cap of 95.2M. Regarding current trading prices, NUVO is priced at $0.17, while RPID trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas RPID's P/E ratio is -1.87. In terms of profitability, NUVO's ROE is -0.37%, compared to RPID's ROE of -1.32%. Regarding short-term risk, NUVO is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check RPID's competition here
NUVO vs ASXC Comparison July 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, NUVO is priced at $0.17, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ASXC's P/E ratio is -1.12. In terms of profitability, NUVO's ROE is -0.37%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, NUVO is less volatile compared to ASXC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ASXC's competition here